Review this exciting guide to some of the recent content additions to Practical Guidance, designed to help you find the tools and insights you need to work more efficiently and effectively. Practical Guidance...
By: Romaine Marshall and Jennifer Bauer , Polsinelli PC This article addresses the broad scope of artificial intelligence (AI) laws in the United States that focus on mitigating risk, and discusses the...
By: Bijan Ghom , Saxton & Stump This article addresses existing deepfake technology and covers topics such as the available platforms to both create and detect deepfakes and the best practices for...
By: Ellen M. Taylor , SLOAN SAKAI YEUNG & WONG LLP THIS ARTICLE ADDRESSES THE BROAD SCOPE OF artificial intelligence (AI) laws in the United States that focus on mitigating risk. AI-driven employment...
By: Jessica Bishop and Sarah Stothart , GOODMANS LLP This checklist provides an overview of key legal considerations attorneys should review when advising clients on negotiating and drafting contracts...
Copyright © 2025 LexisNexis and/or its Licensors.
By: Matthew D. Jenkins, Hunton Andrews Kurth LLP
This article provides an overview of compliance obligations and federal False Claims Act (FCA) risks to healthcare and life sciences companies arising out of three funding streams made available in response to the COVID-19 pandemic: (1) Medicare’s Advance Payment Program, (2) the Provider Relief Fund, and (3) the Paycheck Protection Program.
When you advise a healthcare company that receives federal funds about its compliance obligations, a basic understanding of the FCA is essential.
The FCA imposes civil penalties on persons who knowingly or with reckless disregard: CLICK HERE TO READ THE FULL ARTICLE IF YOU ARE A PRACTICAL GUIDANCE SUBSCRIBER